HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Post-Pandemic Stocks

981.147

+26.2902.75%

Number of Gainers:16

Number of Losers:1

Number of Flat:1

PE:- -

High:984.418

Open:954.770

Low:954.770

Close:954.857

Loading ...

BRIEF-CSPC Pharmaceutical Says JMT108 Obtains Clinical Trial Approval In China

CSPC Pharmaceutical - Approval From National Medical Products Administration of China

THOMSON REUTERS

CSPC Pharmaceutical - Jmt108 (Bi-Functional Fusion Protein Drug) Obtains Clinical Trial Approval in China

THOMSON REUTERS

Chinese Regulator Approves Shanghai Fosun Pharmaceutical's Vaccine for Clinical Trials

MT Newswires Live

CSPC Pharmaceutical Gets Breakthrough Therapy Designation for Anti-Tumor Indication of Sirolimus in China

MT Newswires Live

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Low P/E No Reason For Excitement

Simply Wall St.

Greater China Stocks Close Mixed; Hong Kong Leads Gainers

Despite shrinking by HK$405m in the past week, YiChang HEC ChangJiang Pharmaceutical (HKG:1558) shareholders are still up 74% over 3 years

Simply Wall St.

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Surges 37% Yet Its Low P/S Is No Reason For Excitement

Simply Wall St.

Junshi Biosciences' 2024 Loss Narrows

MT Newswires Live

CSPC Pharmaceutical - Sirolimus for Injection (Albumin-Bound) Was Granted Breakthrough Therapy Designation in China

THOMSON REUTERS

Guangzhou Baiyunshan Pharmaceutical - Disposal of Second New Underlying Assets of Gp Corp. to Industrial Securities Asset Management for RMB583.1 Mln

THOMSON REUTERS

Greater China Stocks Fall; Hong Kong Posts Largest Decline

Fosun Pharmaceutical Secures Clinical Trial Approval for Colorectal Cancer Treatment

MT Newswires Live

BRIEF-Sino Biopharmaceutical Signs Exclusive Strategic Cooperation Agreement With Sciwind Biosciences

Sino Biopharmaceutical - Signing of an Exclusive Strategic Cooperation Agreement With Sciwind Biosciences

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1515/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":981.1467,"timestamp":1741233599172,"preClose":954.8568,"halted":0,"volume":328725323,"delay":0,"changeRate":0.027533,"change":26.289917,"pbRate":1.681623,"amount":3004207965,"amplitude":0.03105,"prevYearClose":787.97723,"fiveDayClose":966.408,"twentyDayClose":851.934,"turnoverRate":0.00446,"marketCap":673756373856,"floatMarketCap":556924631520,"peRate":21.189191},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":984.418,"amplitude":0.03105,"preClose":954.8568,"low":954.7698,"pbRate":"1.681623","latestPrice":981.1467,"volume":328725323,"delay":0,"open":954.7698,"prevYearClose":787.97723,"prevWeekClose":904.791,"prevMonthClose":904.791,"prevQuarterClose":787.977,"fiveDayClose":966.408,"twentyDayClose":851.934,"sixtyDayClose":807.806,"secType":"PLATE","market":"HK","turnoverRate":0.00446,"peRate":21.189191,"marketCap":673756373856,"floatMarketCap":556924631520,"timestamp":1741233599172,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":16,"down":1,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517990772","title":"BRIEF-CSPC Pharmaceutical Says JMT108 Obtains Clinical Trial Approval In China","url":"https://stock-news.laohu8.com/highlight/detail?id=2517990772","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517990772?lang=en_us&edition=fundamental","pubTime":"2025-03-05 19:29","pubTimestamp":1741174199,"startTime":"0","endTime":"0","summary":"BRIEF-CSPC Pharmaceutical Says JMT108 Obtains Clinical Trial Approval In ChinaMarch 5  - CSPC Pharmaceutical Group Ltd 1093.HK:JMT108  OBTAINS CLINICAL TRIAL APPROVAL IN CHINAAPPROVAL FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINAFurther company coverage: 1093.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN12J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287792.SGD","IE0008368742.USD","BK1521","IE00BZ08YR35.GBP","LU1152091754.HKD","IE00B031HY20.USD","LU1226288170.HKD","IE0008369823.USD","LU1152091168.USD","IE00BZ08YS42.EUR","LU1226287529.USD","01093","LU1008478684.HKD","LU1960683339.HKD","LU0326950275.SGD","LU1807302812.USD","IE00B543WZ88.USD","IE00BZ08YT58.USD","BK1191","BK1515","LU0072913022.USD","LU1226288253.USD","SG9999004220.SGD","IE00B5MMRT66.SGD","LU1226287875.USD","LU0067412154.USD","LU0501845795.SGD","LU1951186391.HKD","LU1993786604.SGD","LU0140636845.USD","LU0880133367.SGD"],"gpt_icon":0},{"id":"2517996908","title":"CSPC Pharmaceutical -  Approval From National Medical Products Administration of China","url":"https://stock-news.laohu8.com/highlight/detail?id=2517996908","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517996908?lang=en_us&edition=fundamental","pubTime":"2025-03-05 17:21","pubTimestamp":1741166460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN12J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","IE0008369823.USD","IE00B031HY20.USD","LU0072913022.USD","SG9999004220.SGD","LU1951186391.HKD","BK1515","LU1226288253.USD","LU1008478684.HKD","LU1960683339.HKD","LU0501845795.SGD","IE00B5MMRT66.SGD","LU0067412154.USD","LU1226287529.USD","01093","LU1226287792.SGD","IE0008368742.USD","LU0880133367.SGD","BK1521","IE00B543WZ88.USD","LU1152091168.USD","IE00BZ08YT58.USD","LU1807302812.USD","LU1226288170.HKD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","LU0140636845.USD","LU1993786604.SGD","LU1152091754.HKD","LU0326950275.SGD","LU1226287875.USD"],"gpt_icon":0},{"id":"2517996663","title":"CSPC Pharmaceutical - Jmt108 (Bi-Functional Fusion Protein Drug) Obtains Clinical Trial Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2517996663","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517996663?lang=en_us&edition=fundamental","pubTime":"2025-03-05 17:21","pubTimestamp":1741166460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN12J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1226288253.USD","IE00B031HY20.USD","IE0008369823.USD","LU0501845795.SGD","IE00BZ08YR35.GBP","LU0140636845.USD","LU1152091168.USD","LU0326950275.SGD","IE00B5MMRT66.SGD","LU1960683339.HKD","LU1152091754.HKD","LU1226288170.HKD","LU1226287529.USD","LU1807302812.USD","IE0008368742.USD","LU1226287875.USD","BK1521","LU1226287792.SGD","LU1008478684.HKD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","LU1993786604.SGD","LU0072913022.USD","LU1951186391.HKD","IE00B543WZ88.USD","BK1515","LU0067412154.USD","LU0880133367.SGD","BK1191","01093","SG9999004220.SGD"],"gpt_icon":0},{"id":"2516768536","title":"Chinese Regulator Approves Shanghai Fosun Pharmaceutical's Vaccine for Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2516768536","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516768536?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:07","pubTimestamp":1741093665,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's   subsidiary Fosun Adgenvax  Biopharmaceutical obtained the National Medical Products Administration's approval for clinical trials for its 24-valent pneumococcal polysaccharide conjugate vaccine, a Tuesday bourse filing said.Fosun Adgenvax  Biopharmaceutical plans to start the first phase of clinical trials in China.The vaccine is a preventive biological product used for the prevention of certain infectious diseases caused by certain pneumococcal serotypes.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600196","02196","BK0239","BK1593","BK0096","BK0028","BK0012","BK0187","BK0188","BK0196","BK1191","BK0175","00656","BK1515","BK0060","BK0183"],"gpt_icon":0},{"id":"2516472766","title":"CSPC Pharmaceutical Gets Breakthrough Therapy Designation for Anti-Tumor Indication of Sirolimus in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2516472766","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516472766?lang=en_us&edition=fundamental","pubTime":"2025-03-04 16:47","pubTimestamp":1741078041,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group's  Sirolimus for Injection has been granted breakthrough therapy designation by China's National Medical Products Administration for the intended indication of monotherapy for malignant perivascular epithelioid cell tumor, a Feb. 28 bourse filing said.The oral formulation of sirolimus previously approved for marketing is primarily indicated for the prevention of organ rejection in kidney transplant patients.Sirolimus is currently undergoing multiple phase II and III clinical studies in China for the treatment of solid and hematological tumors.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1226288253.USD","LU1807302812.USD","LU1960683339.HKD","SG9999004220.SGD","LU0326950275.SGD","LU0880133367.SGD","LU1226287529.USD","LU0501845795.SGD","LU1226287792.SGD","IE00B031HY20.USD","01093","LU0140636845.USD","LU1008478684.HKD","LU1993786604.SGD","IE00B5MMRT66.SGD","LU1152091754.HKD","LU1951186391.HKD","IE00B543WZ88.USD","IE00BZ08YT58.USD","IE0008368742.USD","LU0067412154.USD","LU1226288170.HKD","IE0008369823.USD","BK1191","LU1152091168.USD","BK1515","LU1226287875.USD","IE00BZ08YR35.GBP","BK1521","LU0072913022.USD","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2516626639","title":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Low P/E No Reason For Excitement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516626639","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516626639?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:49","pubTimestamp":1741045747,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's ( HKG:874 ) price-to-earnings (or \"P/E\") ratio of 7.8x...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-874/guangzhou-baiyunshan-pharmaceutical-holdings-shares/news/guangzhou-baiyunshan-pharmaceutical-holdings-company-limited-16","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1515","BK1191","BK1521","BK1606","00874","BK1197"],"gpt_icon":0},{"id":"2516502367","title":"Greater China Stocks Close Mixed; Hong Kong Leads Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2516502367","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516502367?lang=en_us&edition=fundamental","pubTime":"2025-03-03 16:30","pubTimestamp":1740990600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Stocks in Greater China were mixed on Monday.Hong Kong's Hang Seng Index rose 0.3% to 23006.27, and China's Shanghai Composite Index slipped 0.1% to 3316.93. The Taiwan Taiex index fell 1.3% to 22756.25.Among Hang Seng constituents, Li Auto Inc. posted the largest decline, falling 4.9%, followed by shares of Semiconductor Manufacturing International Corp., which fell 4.1%. Shares of BYD Electronic  Co. Ltd. fell 3.5%.Xinyi Solar Holdings Ltd. was the biggest gainer among companies on the Hang Seng, surging 8.5%, and JD Health International Inc. surged 5.0%. Alibaba Health Information Technology Ltd. rounded out the top three movers on Monday, as shares gained 3.4%.Among large mainland China stocks, UCloud Technology Co. Ltd. A posted the largest decline, dropping 13%, followed by shares of ASR Microelectronics Co. Ltd. A, which dropped 10%. Shares of Kangxin New Materials Co. Ltd. dropped 10%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","06618","LU1983299162.USD","BK1610","BK1247","BK1526","BK1580","688158","BK1189","IE00BZ08YS42.EUR","LU0274383008.USD","BK1504","BK0245","BK1607","BK1582","BK1142","LU0348767384.USD","BK0214","688369","BK1515","688220","BK1584","BK1591","BK1540","LU0456827905.SGD","BK0251","BK1589","86618","600076","00285","BK1571","IE00BZ08YT58.USD","BK0231","BK0217","688155","BK1502","BK1169","LU0051755006.USD","IE00BZ08YR35.GBP","688776","BK1501","BK1583","BK1149","BK1554","00968","BK1163"],"gpt_icon":1},{"id":"2516994527","title":"Despite shrinking by HK$405m in the past week, YiChang HEC ChangJiang Pharmaceutical (HKG:1558) shareholders are still up 74% over 3 years","url":"https://stock-news.laohu8.com/highlight/detail?id=2516994527","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516994527?lang=en_us&edition=fundamental","pubTime":"2025-03-03 08:46","pubTimestamp":1740962817,"startTime":"0","endTime":"0","summary":"By buying an index fund, you can roughly match the market return with ease. But many of us dare to dream of bigger...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1558/yichang-hec-changjiang-pharmaceutical-shares/news/despite-shrinking-by-hk405m-in-the-past-week-yichang-hec-cha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01558","BK1191","BK1515"],"gpt_icon":0},{"id":"2516527948","title":"Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Surges 37% Yet Its Low P/S Is No Reason For Excitement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516527948","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516527948?lang=en_us&edition=fundamental","pubTime":"2025-03-03 08:36","pubTimestamp":1740962191,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. ( HKG:1877 ) shareholders would be excited to see that the share price has had a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/shanghai-junshi-biosciences-co-ltd-hkg1877-surges-37-yet-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","01877","BK1515","BK1161"],"gpt_icon":0},{"id":"2514342665","title":"Junshi Biosciences' 2024 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2514342665","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514342665?lang=en_us&edition=fundamental","pubTime":"2025-02-28 18:56","pubTimestamp":1740740209,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences'  attributable loss narrowed to 1.28 billion yuan in 2024 from 2.28 billion yuan in 2023, according to a Thursday filing with the Hong Kong Exchange.Loss per share at the drug company fell to 1.30 yuan from 2.32 yuan in the previous year.Total operating income grew 30% to 1.94 billion yuan from 1.50 billion yuan a year earlier.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK1515","01877","688180","BK1161","BK1583"],"gpt_icon":0},{"id":"2514346214","title":"CSPC Pharmaceutical - Sirolimus for Injection (Albumin-Bound) Was Granted Breakthrough Therapy Designation in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514346214","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514346214?lang=en_us&edition=fundamental","pubTime":"2025-02-28 17:55","pubTimestamp":1740736559,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ0VG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1152091168.USD","LU1008478684.HKD","IE00BZ08YT58.USD","BK1515","01093","IE00B543WZ88.USD","LU0072913022.USD","LU1226287792.SGD","BK1521","IE00B031HY20.USD","LU1993786604.SGD","LU1226287529.USD","IE0008368742.USD","LU0326950275.SGD","SG9999004220.SGD","IE00B5MMRT66.SGD","LU1226287875.USD","IE00BZ08YS42.EUR","LU1960683339.HKD","LU1226288253.USD","LU0140636845.USD","LU0501845795.SGD","LU1807302812.USD","LU0880133367.SGD","LU1951186391.HKD","IE0008369823.USD","LU1226288170.HKD","LU1152091754.HKD","BK1191","LU0067412154.USD","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2514479312","title":"Guangzhou Baiyunshan Pharmaceutical - Disposal of Second New Underlying Assets of Gp Corp. to Industrial Securities Asset Management for RMB583.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514479312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514479312?lang=en_us&edition=fundamental","pubTime":"2025-02-28 16:32","pubTimestamp":1740731521,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2JL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK0188","BK1515","BK1197","BK0012","600332","BK0183","BK1521","BK0196","BK0028","BK0175","BK1191","BK0070","00874","BK0096","BK1606","BK0097"],"gpt_icon":0},{"id":"2514122373","title":"Greater China Stocks Fall; Hong Kong Posts Largest Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2514122373","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514122373?lang=en_us&edition=fundamental","pubTime":"2025-02-28 16:30","pubTimestamp":1740731400,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Hong Kong's Hang Seng Index fell 3.3% to 22941.32, and China's Shanghai Composite Index fell 2.0% to 3320.90. Taiwan's stock exchange was closed.Among Hang Seng constituents, BYD Electronic  Co. Ltd. posted the largest decline, dropping 11%, followed by shares of Longfor Group Holdings Ltd., which dropped 8.9%. Shares of Xinyi Solar Holdings Ltd. dropped 8.6%.Galaxy Entertainment Group Ltd. was the biggest gainer among companies on the Hang Seng, gaining 1.9%, and China Shenhua Energy Co. Ltd. gained 1.2%. Sands China Ltd. rounded out the top three movers on Friday, as shares rose 0.5%.Among large mainland China stocks, Cloudwalk Technology Co. Ltd. A posted the largest decline, dropping 16%, followed by shares of Sichuan Huafeng Technology Co. Ltd. A, which dropped 16%. Shares of EFORT Intelligent Equipment Co. Ltd. dropped 15%.KBC Corp. Ltd. A was the biggest gainer during the session, surg","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK0006","688327","LU0594300419.USD","601088","00960","BK0266","LU0607220059.USD","LU1166156734.SGD","BK1149","BK1582","LU0348784397.USD","600734","600665","00027","IE00BZ08YR35.GBP","BK1580","LU1880383366.USD","BK0273","BK1610","LU0417516571.SGD","LU0048597586.USD","LU0384037296.USD","LU1983299162.USD","01088","BK0235","LU0651946864.USD","BK1554","LU0274383008.USD","688598","LU1282649810.SGD","LU0287142896.SGD","BK0188","00285","BK1504","LU0149534421.HKD","BK1169","IE00BZ08YS42.EUR","BK1607","LU0488056044.USD","BK1594","LU1211504680.USD","00968","688165","01928","BK0041","LU1048596156.SGD","SCHYY","LU0228367735.SGD","BK0028"],"gpt_icon":0},{"id":"2514393555","title":"Fosun Pharmaceutical Secures Clinical Trial Approval for Colorectal Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2514393555","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514393555?lang=en_us&edition=fundamental","pubTime":"2025-02-28 12:07","pubTimestamp":1740715674,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  subsidiary Xingsheng Xinhui Pharmaceutical received approval from China's medical products administrator to conduct clinical trials for a colorectal cancer drug.Specifically, the approval was for trials using XS-03 tablets in combination with FOLFOX or FOLFIRI and bevacizumab for the treating RAS-mutated metastatic colorectal cancer, according to a Thursday filing with the Shanghai bourse.Xingsheng Xinhui plans to initiate Phase Ib/II clinical trials for this treatment regimen in mainland China once conditions are met.Shares of the pharmaceutical company were down 1% in recent trade on the Shanghai bourse.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","BK1230","02196","BK0188","BK0239","BK0096","BK0187","BK0196","BK0028","BK1515","BK1593","00656","600196","BK0183","BK0012","BK0175","BK1191"],"gpt_icon":0},{"id":"2514876417","title":"BRIEF-Sino Biopharmaceutical Signs Exclusive Strategic Cooperation Agreement With Sciwind Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2514876417","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514876417?lang=en_us&edition=fundamental","pubTime":"2025-02-27 17:52","pubTimestamp":1740649979,"startTime":"0","endTime":"0","summary":"BRIEF-Sino Biopharmaceutical Signs Exclusive Strategic Cooperation Agreement With Sciwind BiosciencesFeb 27  - Sino Biopharmaceutical Ltd 1177.HK:SIGNING OF AN EXCLUSIVE STRATEGIC COOPERATION AGREEMENT WITH SCIWIND BIOSCIENCES REGARDING PROJECT IL-29SIGNING OF AN EXCLUSIVE STRATEGIC COOPERATION AGREEMENT WITH SCIWIND BIOSCIENCESCO, SCIWIND BIOSCIENCES ESTABLISHED EXCLUSIVITY ON LICENSING AND COOPERATION IN 19 COUNTRIES FOR HUMAN INTERLEUKIN-29 PROJECTFurther company coverage: 1177.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI0KV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","BK1589","BK1515","BK1191","BK1521"],"gpt_icon":0},{"id":"2514822477","title":"Sino Biopharmaceutical - Signing of an Exclusive Strategic Cooperation Agreement With Sciwind Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2514822477","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514822477?lang=en_us&edition=fundamental","pubTime":"2025-02-27 16:40","pubTimestamp":1740645657,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI0KV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1589","01177","BK1515","BK1191","BK1521"],"gpt_icon":0}],"pageSize":16,"totalPage":3,"pageCount":1,"totalSize":39}]}}